EP
SYRE icon

Essential Partners’s Spyre Therapeutics SYRE Stock Holding History

Essential Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$178 Hold
2
– – ﹤0.01% 2621
2026
Q2 		$178 Hold
2
– – ﹤0.01% 2661
2026
Q1 		$101 Buy
+2
New +$75 ﹤0.01% 2713

Other funds holding SYRE

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return

Essential Partners's SYRE Position: Q3 2026 in Review

Essential Partners held its Spyre Therapeutics (SYRE) position steady in Q3 2026 at 2 shares worth $178. The position accounts for ﹤0.01% of the portfolio, ranked #2621.

Essential Partners first reported a position in SYRE in Q1 2026 and has held it in 3 quarters since. 7 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Essential Partners held 2 shares of Spyre Therapeutics worth $178 as of Q3 2026.
  • Essential Partners left its Spyre Therapeutics share count unchanged in Q3 2026.
  • Spyre Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2621 holding.
  • Essential Partners first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 7 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.